Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 5,563 matching trials from the live ClinicalTrials.gov search.

Filters: Sacramento, California Clear all

Conditions: Acute Myeloid Leukemia
Interventions: Atezolizumab, Hu5F9-G4; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Sacramento, California • New Haven, Connecticut • New York, New York + 1 more

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Blood Draw, CSF collection by lumbar puncture (Optional); Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Bevacizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 34
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Interventions: Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Months
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 193
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more

Conditions: Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions: IDO1 Inhibitor BMS-986205, Nivolumab; Drug · Biological
Lead sponsor: Edward Kim; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Stroke, Atrial Fibrillation, Embolism
Interventions: warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 21 Years and older
Enrollment: 21,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 316
States / cities: Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more

Conditions: Influenza
Interventions: Fluarix, Fluzone; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 3,317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more

Conditions: Chronic Sinusitis
Interventions: SinuNase; Drug
Lead sponsor: Accentia Biopharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 68
States / cities: Birmingham, Alabama • Gilbert, Arizona • Jonesboro, Arkansas + 60 more

Conditions: Alcoholic Intoxication
Interventions: Brief motivational interview; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Fragile X Syndrome (FXS)
Interventions: OV101 (gaboxadol); Drug
Lead sponsor: Ovid Therapeutics Inc.; Industry
Eligibility: 13 Years to 22 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Sacramento, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Septic Shock
Interventions: Levo-Carnitine, placebo; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Sacramento, California • Wilmington, Delaware + 9 more

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 127
States / cities: Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 117 more

Conditions: Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel; Procedure · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 883
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Interventions: lisocabtagene maraleucel; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 59
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 19 more

Conditions: Seizures Associated With EMAS
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more

Conditions: Tricuspid Regurgitation
Interventions: TriClipTM Device; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more

Conditions: Achilles Tendon Injury
Interventions: VersaWrap; Device
Lead sponsor: Research Source; Network
Eligibility: 18 Years to 90 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Sacramento, California • Philadelphia, Pennsylvania • Charleston, South Carolina

Conditions: Schizophrenia
Interventions: Transcranial Direct Current Stimulation; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 35 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Childhood Embryonal Tumor, Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIC Ovarian Germ Cell Tumor, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma
Interventions: conventional surgery, cisplatin, etoposide, bleomycin sulfate, laboratory biomarker analysis; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 112
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 98 more

Conditions: Peripheral Arterial Disease, Clopidogrel, Poor Metabolism of
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Non-Alcoholic Steatohepatitis
Interventions: EDP-305 1.5 mg, EDP-305 2 mg, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 68
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 57 more

Conditions: Intracerebral Hemorrhage
Interventions: Recombinant Factor VIIa, Biological/Vaccine: Placebo; Biological
Lead sponsor: Joseph Broderick, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 38 more

Conditions: Burns, Wound Heal, Wounds and Injuries
Interventions: DeepView SnapShot Portable (DV-SSP); Device
Lead sponsor: SpectralMD; Industry
Eligibility: Not listed
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 17 more

Conditions: Sepsis
Interventions: Fluid Resuscitation, Standard of Care; Other
Lead sponsor: Cheetah Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 12
States / cities: Birmingham, Alabama • Sacramento, California • Denver, Colorado + 7 more

Search by objective public record fields.

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

Amphotericin B Suspension in Refractory Chronic Sinusitis

Behavior and Driving Safety Study

A Study of OV101 in Individuals With Fragile X Syndrome

Rapid Administration of Carnitine in sEpsis

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

TRILUMINATE Pivotal Trial

Outcomes for VersaWrap in Achilles Tendon Repair

The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia

Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Burn Validation Study

Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis